PropertyValue
?:abstract
  • Preliminary data from a small study of an experimental COVID-19 vaccine developed by Moderna suggest that the vaccine is safe and can spur the immune system to produce antibodies that neutralize SARS-CoV-2, the coronavirus that causes the disease It’s the first time that results from any COVID-19 vaccine study in humans have been announced The news, disclosed May 18, quickly swept the globe and was widely credited as a catalyst for a rise in the stock market Moderna’s stock soared more than 20%, putting the company’s value at nearly $30 billion—versus about $6 5 billion at the start of the year The biotech firm said it would raise $1 25 billion in a public stock offering and put the money toward manufacturing its COVID-19 vaccines But scientists hoping to parse the news themselves are out of luck “I was disappointed that they didn’t disclose any data It is hard to interpret their[truncated]
?:creator
?:journal
  • C&EN_Global_Enterprise
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Moderna provides cursory glance at first COVID-19 vaccine data
?:type
?:who_covidence_id
  • #378794
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/27p32p4h>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/27p32p4h>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all